Involving Co-transfection Patents (Class 435/465)
-
Publication number: 20120263689Abstract: Methods and compositions for generating adipose-derived induced pluripotent stem cells for humans and animals and their use are provided.Type: ApplicationFiled: September 10, 2010Publication date: October 18, 2012Applicant: The Salk Institute for Biological StudiesInventors: Shigeki Sugii, Ronald M. Evans, Juan Carlos Izpisua Belmonte, Yasuyuki Kida
-
Patent number: 8211631Abstract: A population of iPS cells derived from somatic cells from a spinal muscular atrophy patient is disclosed. In one embodiment of the invention, the cells have been cultured to produce neural cells. In another embodiment, the invention is a method of testing compounds for their ability to modify cellular SMN levels comprising the steps of obtaining a population of iPS cells derived from a spinal muscular atrophy patient or cells derived from the iPS cells, and examining the effect of a test compound on SMN levels.Type: GrantFiled: December 18, 2009Date of Patent: July 3, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Clive Svendsen, Allison Ebert
-
Publication number: 20120135015Abstract: Methods for generating pancreatic stem cells from a pancreatic tissue of 24-week old mice by transient overexpression of reprogramming factors combined with Pdx1 selection is described herein. The generated cells were designated as iPaS (induced pancreatic stem) cells and exhibit the same morphology as the pancreatic stem cells previously established from young donors without genetic manipulation and express genetic markers of endoderm and pancreatic progenitors. Transplantation of the iPaS cells into nude mice resulted in no teratoma formation. Moreover, iPaS cells were able to differentiate into insulin-producing cells more efficiently than ES cells. In addition, the technology of transient overexpression of reprogramming factors and tissue-specific selection of the present invention may also be useful for the generation of other tissue-specific stem cells.Type: ApplicationFiled: September 19, 2011Publication date: May 31, 2012Applicant: Baylor Research InstituteInventors: Hirofumi Noguchi, Marlon F. Levy, Shinichi Matsumoto
-
Publication number: 20120115233Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.Type: ApplicationFiled: August 16, 2011Publication date: May 10, 2012Applicant: Intrexon CorporationInventor: Subba Reddy PALLI
-
Publication number: 20120027847Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: January 21, 2010Publication date: February 2, 2012Applicant: NS GENE A/ASInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Patent number: 8097277Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: November 19, 2010Date of Patent: January 17, 2012Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Patent number: 8088621Abstract: The instant invention provides methods and compositions for generating recombinant adenoviral vectors. The invention also provides kits comprising for the generation of recombinant adenoviral vectors.Type: GrantFiled: September 14, 2007Date of Patent: January 3, 2012Assignee: The Johns Hopkins UniversityInventors: Ronald Rodriguez, Shawn Edward Lupold, Wasim Haider Chowdhury, Tarana A. Kudrolli
-
Publication number: 20110277050Abstract: Embodiments of the present invention describe a novel and versatile inducible binary expression system (the ‘Q system’) and methods for controlling transgene expression in vitro and in vivo, for lineage tracing, for genetic mosaic analysis and for determining gene function.Type: ApplicationFiled: March 11, 2011Publication date: November 10, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Liqun Luo, Christopher Potter, Bosiljka Tasic
-
Publication number: 20110263028Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.Type: ApplicationFiled: October 23, 2009Publication date: October 27, 2011Applicant: CellectisInventors: Jean-Pierre Cabaniols, André Choulika, Christophe Delenda
-
Patent number: 8034620Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: November 9, 2007Date of Patent: October 11, 2011Assignee: Bluebird Bio, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7892834Abstract: A gene complex-forming material which comprises a water-soluble polymer having a peptide containing an amino acid sequence serving as the substrate of an intracellular signal-responsive enzyme and basic amino acids imparting cationic nature; a gene complex composed of this gene complex-forming material with a gene; and a gene transfer method and a gene transfer agent with the use of the same. Namely, a novel material and a method wherein the cationic moiety of the peptide and the gene form a rigid ion complex to give a stable gene complex, and, upon a cellular signal response, the positive charge of the cationic moiety of the peptide is neutralized or disappears and the gene complex is broken in the cell to thereby release the gene, thus activating the gene transferred into specific cells. The neutralization or disappearance of the positive charge can be achieved by, for example, phosphorylation with protein kinase A or cleavage by caspase.Type: GrantFiled: October 16, 2001Date of Patent: February 22, 2011Assignee: Japan Science and Technology AgencyInventor: Yoshiki Katayama
-
Publication number: 20110039339Abstract: Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).Type: ApplicationFiled: March 9, 2009Publication date: February 17, 2011Inventors: Yves Durocher, Martin Loignon
-
Patent number: 7883720Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: July 7, 2004Date of Patent: February 8, 2011Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Publication number: 20110016548Abstract: Provided are methods for controlling endogenous gene expression comprising control of the DNA methyltransferase (Dnmt1) for modulation of DNA methylation and epigenetic mechanisms. Provided are transcriptional regulatory systems involving multiple (e.g., three) exogenous binary systems, lacI, tetR and Gal4, for reversible up/down regulation of endogenous target genes Provided are lac operator and repressor modifications for improved repression relative to wild type (WT) lac and tet systems. Provided are endogenous Dnmt1 promoter modifications, comprising targeted lac operator sequences that do not significantly alter promoter activity absent repressors, yet show substantially reduced expression of the targeted allele upon lac repressor introduction. The lacO targeted Dnmt1 allele is introducible into the mouse germline, to provide a respective upregulatable transcriptional control system in vivo (e.g.Type: ApplicationFiled: July 16, 2010Publication date: January 20, 2011Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: PETER W. LAIRD, KWANGHO LEE
-
Publication number: 20100311172Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. Provided are means and methods for reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: ApplicationFiled: July 14, 2010Publication date: December 9, 2010Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20100311116Abstract: The present invention provides a novel method for the fast generation of high expression stable cell lines for the production of recombinant proteins with high efficacy of stable integration while using low selective pressure for only a short period of time. The method uses transiently expressed piggybac transposase to mediate stable integration of a transgene of interest flanked by the PB transposon termini.Type: ApplicationFiled: June 4, 2009Publication date: December 9, 2010Applicant: EXCELLGENE SAInventors: Florian M. Wurm, Markus Hildinger, Maria De Jesus, Mattia Matasci, David Hacker
-
Publication number: 20100240133Abstract: PiggyBac transposons and transposases with enhanced transposition activity in cells are provided. Also provided are associated methods and kits for both introducing exogenous DNA inserts into the genomes of host cells as well as for the removal of the inserts from the host cell genomes. Cells obtained by use of the compositions, methods and kits are also provided.Type: ApplicationFiled: March 22, 2010Publication date: September 23, 2010Applicant: THE ROCKEFELLER UNIVERSITYInventors: Ali Brivanlou, Arnaud Lacoste
-
Publication number: 20100233202Abstract: A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.Type: ApplicationFiled: February 8, 2007Publication date: September 16, 2010Inventors: Shigeto Yoshida, Yoshio Ohba, Norimitsu Hariguchi, Masami Mizukoshi, Masanori Kawasaki, Makoto Matsumoto, Yoshihiro Goto
-
Patent number: 7790419Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.Type: GrantFiled: January 27, 2003Date of Patent: September 7, 2010Assignee: Oxford Biomedica (UK) Ltd.Inventors: Alan John Kingsman, Kyriacos Mitrophanous, Narry Kim
-
Patent number: 7732207Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.Type: GrantFiled: March 21, 2007Date of Patent: June 8, 2010Assignees: California Institute of Technology, The Regents of the University of CaliforniaInventors: Xiao-Feng Qin, David Baltimore, Irvin S. Y. Chen, Dong Sung An
-
Publication number: 20100055794Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.Type: ApplicationFiled: November 6, 2009Publication date: March 4, 2010Inventors: Jeffrey T. McGrew, Allison A. Bianchi
-
Patent number: 7655834Abstract: By analyzing the causative gene of tt19 mutants and elucidating the nature of the mutants, the present inventors found a novel gene as the causative gene and gave it the name TRANSPARENT TESTA (TT19) gene. The inventors cloned this gene and analyzed its DNA nucleotide sequence as well as the protein encoded by its DNA. The inventors also provided a transformed plant utilizing the nature of the identified causative gene.Type: GrantFiled: March 11, 2004Date of Patent: February 2, 2010Assignee: Japan Atomic Energy Research InstituteInventors: Satoshi Kitamura, Naoya Shikazono, Atsushi Tanaka
-
Patent number: 7638331Abstract: The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked to at least one AIG such that the COX-2 promoter is activated in cells that overexpress COX-2, thereby resulting in transcription and translation of the AIG, which in turn activates apoptosis in the cell. Thus, apoptosis is selectively induced in only those cells capable of overexpressing COX-2.Type: GrantFiled: December 23, 2004Date of Patent: December 29, 2009Assignee: The Administration of the Tulane Rducation FundInventors: W. Terrance Godbey, Anthony Atala
-
Publication number: 20090208515Abstract: The present invention relates to virus vectors comprising oligonucleotides encoding HIV polypeptides, more particularly wherein the virus vector is an adenovirus. In particular, such adenoviruses are non-human primate adenoviruses such as simian adenoviruses, more particularly chimpanzee adenoviruses. In particular the invention relates to adenovirus vectors which comprise HIV polynucleotide sequences which encode multiple different HIV antigens, for example two or three or more HIV antigens. The invention further relates to methods of preparing the virus vectors, to the virus vectors produced by the methods and to the use of the vectors in medicine especially prophylactic or therapeutic vaccination.Type: ApplicationFiled: May 10, 2006Publication date: August 20, 2009Inventors: Peter Franz Ertl, John Philip Tite, Catherine Ann Van Wely
-
Publication number: 20090162396Abstract: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.Type: ApplicationFiled: February 25, 2009Publication date: June 25, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, GMBHInventors: Antonie Neubauer, Christina Ziegler
-
Publication number: 20090148950Abstract: A method of producing a packaged DNA sequence is disclosed. In one embodiment, the method comprises the steps of: (a) selecting a DNA sequence to be packaged and a papillomaviral capsid sequence, wherein the DNA sequence to be packaged is between 7 Kb-8.5 Kb, (b) co-transfecting the products of step (a) into transfectable cells, wherein the DNA sequence is packaged, and (c) purifying packaged particles.Type: ApplicationFiled: January 30, 2006Publication date: June 11, 2009Inventors: Paul G. Ahlquist, Dohun Pyeon, Paul F. Lambert
-
Publication number: 20090075384Abstract: The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5? replication recognition sequence, wherein at least one initiation codon has been removed from the 5? replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3? replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5? and 3? replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.Type: ApplicationFiled: June 20, 2008Publication date: March 19, 2009Inventors: Kurt I. Kamrud, Jonathan F. Smith, Maureen Maughan
-
Publication number: 20090029354Abstract: The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.Type: ApplicationFiled: November 6, 2006Publication date: January 29, 2009Applicants: NON-PROFIT ORGANIZATION CHANG GUNG MEMORIAL HOSPITAL, CHANG GUNG UNIVERSITYInventors: Joseph Tung-Chieh Chang, Ann-Joy Cheng, Yin-Ju Chen
-
Publication number: 20080261274Abstract: Gene complementation is used to restore cholesterol independence in NS lineage murine myeloma cells, such as NSO and NS 1, yielding a selectable system for recombinant production of polynucleotides and polypeptides.Type: ApplicationFiled: March 10, 2006Publication date: October 23, 2008Inventors: Wei-shou Hu, Gargi Seth
-
Patent number: 7439037Abstract: Use of aminoglycoside resistance gene product for achieving high-density growth of animal cells.Type: GrantFiled: September 26, 2002Date of Patent: October 21, 2008Assignees: Lonza Biologics PLCInventors: Mohamed Al-Rubeai, Angelo Perani, Andy Racher, John Birch
-
Publication number: 20080241930Abstract: This document involves methods and materials related to obtaining Paramyxoviridae virus preparations.Type: ApplicationFiled: July 14, 2006Publication date: October 2, 2008Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Mark J. Federspiel, Troy R. Wegman, Kirsten K. Langfield, Henry J. Walker
-
Publication number: 20080145937Abstract: The present invention includes compositions and methods for transforming cells into glucose-responsive, insulin-production cells using a construct that expresses betacellulin and PDX1, e.g., transforming pancreatic acinar cells using one or more expression vectors that expressed betacellulin and PDX1 using ultrasound targeted microbubble destruction (UTMD).Type: ApplicationFiled: September 21, 2007Publication date: June 19, 2008Applicant: BAYLOR RESEARCH INSTITUTEInventors: Paul A. Grayburn, Shuyuan Chen
-
Patent number: 7361641Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: GrantFiled: August 5, 2003Date of Patent: April 22, 2008Assignee: The Board of Trustees of The Leland Stanford Junior UniversityInventor: Michele Pamela Calos
-
Patent number: 7335505Abstract: The present invention provides methods of proteolytically converting a precursor protein (e.g. tau) to a product fragment (e.g., a 12 kd fragment) in a stable cell line, wherein the precursor protein is associated with a disease state in which the precursor protein aggregates pathologically (e.g. a tauopathy), and the methods comprise: (a) providing a stable cell line transfected with nucleic acid encoding: (i) a template fragment of the precursor protein such that the template fragment is constitutively expressed in the cell at a level which is not toxic to the cell; and (ii) the precursor protein, which protein is inducibly expressed in the cell in response to a stimulus, whereby interaction of the template fragment with the precursor protein causes a conformational change in the precursor protein such as to cause aggregation and proteolytic processing of the precursor protein to the product fragment.Type: GrantFiled: January 15, 2002Date of Patent: February 26, 2008Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, David Horsley, Janet Elizabeth Rickard, Charles Robert Harrington
-
Patent number: 7332333Abstract: The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector. Suitable integrating vectors for use in the present invention include retrovirus vectors, lentivirus vectors, transposon vectors, and adeno-associated virus vectors. Methods are provided in which the host cells are prepared by using the integrating vectors at a high multiplicity of infection. The host cells are useful for producing pharmaceutical proteins, variants of proteins for use in screening assays, and for direct use in high throughput screening.Type: GrantFiled: December 21, 2004Date of Patent: February 19, 2008Assignee: Gala Design, Inc.Inventors: Robert D. Bremel, Linda U. Miller, Gregory T. Bleck
-
Patent number: 7311907Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.Type: GrantFiled: April 5, 2005Date of Patent: December 25, 2007Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 7250293Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35-E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.Type: GrantFiled: October 15, 2002Date of Patent: July 31, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
-
Patent number: 7241600Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine.Type: GrantFiled: June 14, 2002Date of Patent: July 10, 2007Assignee: Degussa AGInventor: Mechthild Rieping
-
Patent number: 7202079Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: April 10, 2007Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 7195916Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.Type: GrantFiled: December 12, 2002Date of Patent: March 27, 2007Assignee: California Institute of TechnologyInventors: Xiao-Feng Qin, David Baltimore
-
Patent number: 7179595Abstract: The present invention provides non-single-chain antigen-binding units that is stabilized by leucine zipper sequences. The experimental design is particularly useful for generating and screening for Nsc Abus that remain the binding capabilities to their respective antigens within a cell. The present invention also provides recombinant polynucleotides, host cells and kits comprising the vectors. Further provided by the invention are methods of using the subject vectors.Type: GrantFiled: August 22, 2002Date of Patent: February 20, 2007Inventor: Shengfeng Li
-
Patent number: 7125712Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.Type: GrantFiled: March 8, 2005Date of Patent: October 24, 2006Assignee: Novartis AGInventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
-
Patent number: 6977297Abstract: GSL-ELONGASE gene of Arabidopsis thaliana and other plants, especially Brassica oleracea, Brassica rapa and Brassica napus. The nature and level of glucosinolates in plants can be modified by transgenic expression of the genes or control of the level of expression.Type: GrantFiled: November 23, 1998Date of Patent: December 20, 2005Assignee: Plant Bioscience LimitedInventor: Richard F. Mithen
-
Patent number: 6958226Abstract: Novel packaging cell lines useful for generating viral accessory protein independent HIV-derived retroviral vector particles, methods of constructing such packaging cell lines and methods of using the viral accessory protein independent HIV-derived retroviral vector particles are disclosed.Type: GrantFiled: September 10, 1999Date of Patent: October 25, 2005Assignee: The Children's Medical Center Corp.Inventors: John T. Gray, Jeng-Shin Lee, Richard C. Mulligan
-
Patent number: 6955919Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.Type: GrantFiled: April 1, 2002Date of Patent: October 18, 2005Assignee: Genetix Pharmaceuticals, Inc.Inventors: Philippe Leboulch, Karen Westerman
-
Patent number: 6951754Abstract: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuramimidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus.Type: GrantFiled: April 27, 2001Date of Patent: October 4, 2005Assignee: St. Jude Children's Research HospitalInventor: Erich Hoffmann
-
Patent number: 6916611Abstract: An expression vector system comprising a pair of expression vectors constructed from a wild-type and a mutant version of a maker, reporter or selection gene, and a method for optimization and confirmation of DNA delivery and of gene targeting and for quantification of targeting frequency. Novel prokaryotic/eukaryotic DNA vectors used for DNA delivery and gene targeting assessment and targeting frequency quantification.Type: GrantFiled: February 26, 2001Date of Patent: July 12, 2005Assignee: The Regents of the University of CaliforniaInventors: Kaarin Kerr Goncz, Dieter Cotter Gruenert, Alessia Colosimo
-
Patent number: 6913922Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5, and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: GrantFiled: May 18, 2000Date of Patent: July 5, 2005Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Patent number: 6890716Abstract: This invention provides recombinant cell lines and screening methods useful for identifying agents that induce apoptosis in target cells and therefore may be used to advantage in the treatment of neoplastic disorders.Type: GrantFiled: May 6, 1999Date of Patent: May 10, 2005Assignee: Howard Hughes Medical InstituteInventors: Eileen White, Anju Thomas, Gary Kasof, Lakshmi Goyal
-
Patent number: 6855513Abstract: The invention provides methods for identifying a modulator of quorum sensing signaling in bacteria, and for identifying a quorum sensing controlled gene in bacteria. In addition, the invention provides quorum sensing controlled genetic loci in Pseudomas aeruginosa. Novel indicator strains and vectors for engineering the strains for use in the method of the invention are also provided.Type: GrantFiled: September 1, 2000Date of Patent: February 15, 2005Assignees: University of Iowa Research Foundation, Vertex Pharmaceuticals (San Diego) LLCInventors: Marvin Whiteley, Kimberly M. Lee, E. Peter Greenberg, Ute Muh